Clinical trial NCT00504413 - References

Substance-Related Disorders — Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Citation(s)

•   Allen DM
  The prediction sum of squares as a criterion for selecting predictor variables. In University of Ky Dept of Statistics Tech Report 23, 1971
•   Beckett AH, Taylor JF, Casy AF, Hassan MM
  The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol. 1968 Oct;20(10):754-62.
•   Begré S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB
  Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002 Apr;22(2):211-5.
•   Bouër R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G
  The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol. 1999;13(4):494-500.
•   Boulton DW, Arnaud P, DeVane CL
  Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther. 2001 Jul;70(1):48-57.
•   Brettle RP
  HIV and harm reduction for injection drug users. AIDS. 1991 Feb;5(2):125-36. Review.
•   Bruera E, Kim HN
  Cancer pain. JAMA. 2003 Nov 12;290(18):2476-9. Review.
•   Callaghan R, Riordan JR
  Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993 Jul 25;268(21):16059-64.
•   Caplehorn JR, Drummer OH
  Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999 Feb 1;170(3):104-9.
•   Charlier C, Dessalles MC, Plomteux G
  Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient? Ther Drug Monit. 2001 Feb;23(1):1-3.
•   Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB
  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005 Dec;78(6):593-604.
•   de Boer AG, van der Sandt IC, Gaillard PJ
  The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2003;43:629-56. Epub 2002 Jan 10. Review.
•   Doherty JE, Flanigan WJ, Murphy ML, Bulloch RT, Dalrymple GL, Beard OW, Perkins WH
  Tritiated digoxin. XIV. Enterohepatic circulation, absorption, and excretion studies in human volunteers. Circulation. 1970 Nov;42(5):867-73.
•   Eap CB, Buclin T, Baumann P
  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. Review.
•   Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL
  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
•   Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F
  Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000 Nov;50(5):427-40.
•   Fricker G, Miller DS
  Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol. 2002 Jan;90(1):5-13. Review.
•   Fromm MF
  P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000 Feb;38(2):69-74. Review.
•   Gerber JG, Rhodes RJ, Gal J
  Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004 Jan;16(1):36-44.
•   Gourlay GK, Cherry DA, Cousins MJ
  A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986 Jun;25(3):297-312.
•   Hanna J, Foster DJ, Salter A, Somogyi AA, White JM, Bochner F
  Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. Br J Clin Pharmacol. 2005 Oct;60(4):404-13.
•   Hesse LM, Sakai Y, Vishnuvardhan D, Li AP, von Moltke LL, Greenblatt DJ
  Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol. 2003 Sep;55(9):1229-39.
•   Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA
  Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997 Aug;37(8):737-43.
•   Inturrisi CE, Verebely K
  Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):923-30.
•   Iribarne C, Dréano Y, Bardou LG, Ménez JF, Berthou F
  Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997 Feb 14;117(1):13-23.
•   Jabor VA, Coelho EB, Dos Santos NA, Bonato PS, Lanchote VL
  A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):27-32.
•   Kharasch ED, Hoffer C, Whittington D, Sheffels P
  Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69.
•   Kharasch ED, Hoffer C, Whittington D
  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol. 2004 May;57(5):600-10.
•   Klotz U, Antonin KH
  Biliary excretion studies with digoxin in man. Int J Clin Pharmacol Biopharm. 1977 Jul;15(7):332-4.
•   Kreek MJ, Vocci FJ
  History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002 Sep;23(2):93-105. Review.
•   Kristensen K, Christensen CB, Christrup LL
  The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45-50.
•   Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E
  MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 Apr;79(4):325-38. Epub 2006 Feb 20.
•   Lin JH, Yamazaki M
  Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59-98. Review.
•   Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G
  Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006 Jan;79(1):72-89.
•   Manfredi PL, Borsook D, Chandler SW, Payne R
  Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain. 1997 Mar;70(1):99-101.
•   Martin H, Sarsat JP, de Waziers I, Housset C, Balladur P, Beaune P, Albaladejo V, Lerche-Langrand C
  Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res. 2003 Apr;20(4):557-68.
•   Mattick RP, Breen C, Kimber J, Davoli M
  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD002209.
•   Mercadante S
  Methadone in cancer pain. Eur J Pain. 1997;1(2):77-83; discussion 84-5.
•   Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF
  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003 Jul;45(1):122-32.
•   Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W
  Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin Pharmacol Ther. 2004 Aug;76(2):154-66.
•   Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT
  Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003;42(9):819-50. Review.
•   Oda Y, Kharasch ED
  Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001 Sep;298(3):1021-32.
•   Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K
  Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003 Oct;74(4):326-33.
•   Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM
  The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. Review.
•   Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ
  The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003 Feb 17;1619(3):243-53. Review.
•   Peles E, Schreiber S, Gordon J, Adelson M
  Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005 Feb;113(3):340-6.
•   Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H
  Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. Review.
•   Ripamonti C, Bianchi M
  The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002 Jun;16(3):543-55. Review.
•   Rosner B
  Fundamentals of Biostatistics. Duxbury, 2006.
•   Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB
  Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 2003 Mar 1;69(2):205-11.
•   Sorensen JL, Copeland AL
  Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000 Apr 1;59(1):17-31. Review.
•   Stenbacka M, Leifman A, Romelsjö A
  The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods. Drug Alcohol Rev. 2003 Mar;22(1):27-34.
•   Störmer E, Perloff MD, von Moltke LL, Greenblatt DJ
  Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6.
•   Streetman DS, Bertino JS Jr, Nafziger AN
  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 Apr;10(3):187-216. Review.
•   Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr
  Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct;68(4):375-83.
•   Thompson SJ, Koszdin K, Bernards CM
  Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000 May;92(5):1392-9.
•   Tracqui A, Kintz P, Ludes B, Mangin P
  High-performance liquid chromatography-ionspray mass spectrometry for the specific determination of digoxin and some related cardiac glycosides in human plasma. J Chromatogr B Biomed Sci Appl. 1997 Apr 25;692(1):101-9.
•   Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O
  Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos. 2004 Jun;32(6):626-31.
•   Wang JS, DeVane CL
  Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003 Jun;31(6):742-7.
•   Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL
  Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl). 2004 Apr;173(1-2):132-8. Epub 2004 Jan 8.
•   Ward J, Mattrick R, Hall W
  Methadone maintenance treatment and other opioid replacement therapies. Harwood Academic Publishers, Amsterdam. 1998
•   Whittington D, Sheffels P, Kharasch ED
  Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):313-21.
•   Wong KH, Lee SS, Lim WL, Low HK
  Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003 Apr;24(3):233-9.

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects

Details for clinical trial NCT00504413